Intec gets Canadian patent for Accordion Pill controlled release tech

By Flora Southey

- Last updated on GMT

GettyImages/HomePixel
GettyImages/HomePixel

Related tags Pharmacology

Canadian regulators have granted Intec Pharma a patent for its Accordion Pill controlled release technology.

The patent​ covers the technology in combination with Carbidopa and Levodopa (AP-CD/LD) – currently in a Phase III trial for advanced Parkinson’s disease – until April 2029.

The Accordion Pill fits inside a standard size capsule, and is composed of a multi-layer, planar structure, reminiscent of an accordion.

According to Intec, when the capsule reaches the stomach, the capsule unfolds, and the accordion structure made of pharmaceutical biodegradable polymeric films, dissolves.

The structure remains in the stomach for up to 12 hours said the firm, allowing it to release the drug into the upper gastrointestinal tract in a controlled manner.  

“Retaining the dosage form in the stomach and releasing the drug in a controlled manner enable prolonged and continuous absorption phase of the drug in the upper part of the gastrointestinal tract, resulting in improved efficacy and safety profile, as well as reduced frequent daily dosing,” ​said the firm.

The pill is suitable for drugs that are poorly soluble. It can be used to combine immediate and controlled-release drugs, and deliver more than one active pharmaceutical ingredient (API) at the same time.

The firm said it plans to increase its patent portfolio, which includes the US, Europe, China, Japan, South Korea, Hong Kong, South Africa, and Israel.  

Cannabinoid carrier

Intec is also developing an Accordion Pill combination treatment using cannabidiol and tetrahydrocannabinol (AP-CBD/THC) for indications including low back neuropathic pain and fibromyalgia.

The Israel-headquartered firm said AP-CBD/THC could help address drawbacks in current methods of use with cannabis and cannabinoids, such as short duration of effect and delayed onset.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers